| pubmed-article:21522004 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21522004 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:21522004 | lifeskim:mentions | umls-concept:C0008972 | lld:lifeskim |
| pubmed-article:21522004 | lifeskim:mentions | umls-concept:C1871526 | lld:lifeskim |
| pubmed-article:21522004 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:21522004 | lifeskim:mentions | umls-concept:C0449560 | lld:lifeskim |
| pubmed-article:21522004 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:21522004 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:21522004 | pubmed:dateCreated | 2011-6-29 | lld:pubmed |
| pubmed-article:21522004 | pubmed:abstractText | We evaluated the long-term efficacy of raltegravir according to HIV-1 subtype (B and non-B) using data from three phase III studies in treatment-experienced (BENCHMRK-1 and 2) and treatment-naive (STARTMRK) HIV-infected patients. | lld:pubmed |
| pubmed-article:21522004 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21522004 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522004 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21522004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21522004 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21522004 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21522004 | pubmed:issn | 1473-5571 | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:MillerMichael... | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:ZhaoJingJ | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:RockstrohJürg... | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:TepplerHedyH | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:HarveyCharlot... | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:LeavittRandi... | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:SklarPeterP | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:StrohmaierKim... | lld:pubmed |
| pubmed-article:21522004 | pubmed:author | pubmed-author:NguyenBach-Ye... | lld:pubmed |
| pubmed-article:21522004 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21522004 | pubmed:day | 17 | lld:pubmed |
| pubmed-article:21522004 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:21522004 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21522004 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21522004 | pubmed:pagination | 1365-9 | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:meshHeading | pubmed-meshheading:21522004... | lld:pubmed |
| pubmed-article:21522004 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21522004 | pubmed:articleTitle | Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. | lld:pubmed |
| pubmed-article:21522004 | pubmed:affiliation | University of Bonn, Bonn-Venusberg, Germany. | lld:pubmed |
| pubmed-article:21522004 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21522004 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21522004 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21522004 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21522004 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
